Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy
Authors
Eichinger, KatyHeatwole, Chad
Heininger, Susanne
Stinson, Nikia
Matichak Stock, Carly
Grosmann, Carla
Wagner, Kathryn R.
Tawil, Rabi
Statland, Jeffrey M.
FSHD Clinical Trials Research Network
UMass Chan Affiliations
Wellstone Center for FSHDDocument Type
Journal ArticlePublication Date
2017-03-01Keywords
6 Minute Walk Testclinical trials
facioscapulohumeral muscular dystrophy
neuromuscular disease
outcome measures
Cell Biology
Developmental Biology
Molecular Biology
Molecular Genetics
Musculoskeletal Diseases
Nervous System Diseases
Metadata
Show full item recordAbstract
INTRODUCTION: In preparation for future clinical trials, we determined the reliability, relationship to measures of disease severity, and consistency across sites of the 6 Minute Walk Test (6MWT) in patients with facioscapulohumeral muscular dystrophy (FSHD). METHODS: Genetically defined and clinically affected FSHD participants at 2 sites performed the 6MWT, the Timed Up and Go, and the 30 foot Go/Timed 10 meter test as measures of mobility using standard procedures. RESULTS: Eight-six participants representing the full range of severity performed the 6MWT. The mean 6MWT distance was 404.3 meters (SD 123.9), with no difference between sites. The 6MWT was reliable (n = 25; intraclass correlation coefficient = 0.99) and demonstrated moderate to strong correlations with lower extremity strength, functional outcomes, and FSHD Clinical Score. CONCLUSIONS: The 6MWT is reliable and is associated with other measures of FSHD disease severity. Future directions include assessing its sensitivity to disease progression. .Source
Muscle Nerve. 2017 Mar;55(3):333-337. doi: 10.1002/mus.25251. Epub 2016 Dec 5. Link to article on publisher's siteDOI
10.1002/mus.25251Permanent Link to this Item
http://hdl.handle.net/20.500.14038/50568PubMed ID
27421252Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1002/mus.25251